1. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
- Author
-
Jana K. Striefler, Fritz Klein, Bruno Valentin Sinn, Marianne Sinn, Philipp Lohneis, Anja Jühling, Hanno Riess, Sven Bischoff, Uwe Pelzer, Hendrik Bläker, Carsten Denkert, Lilianna Wislocka, and Helmut Oettle
- Subjects
Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,Clinical cohort ,Colorectal cancer ,Gastroenterology ,Disease-Free Survival ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Carcinoma ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Tumor Burden ,Pancreatic Neoplasms ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Tumour budding ,Female ,Neoplasm Grading ,business ,Carcinoma, Pancreatic Ductal - Abstract
Background The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial. Methods Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0.238 mm2). Results Tumour budding was significantly associated with a higher tumour grade (p
- Published
- 2018
- Full Text
- View/download PDF